Literature DB >> 2463902

Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes.

D D Bikle1, E Gee.   

Abstract

Greater than 99% of the total circulating 1,25-dihydroxyvitamin D [1,25-(OH)2D] is bound to proteins such as the vitamin D-binding protein (DBP) and albumin; in the normal human only 0.4% of the circulating 1,25-(OH)2D is free. Although it is often assumed that only the free concentration of 1,25-(OH)2D is available to cells, this has not been demonstrated. In particular, it is not clear whether the DBPs facilitate 1,25-(OH)2D entry into target cells or serve only to transport these metabolites within the circulation. To address this question, we evaluated one of the best characterized target tissue responses to 1,25-(OH)2D, namely its ability to inhibit its own production and induce that of 24,25-(OH)2D, using one of the most sensitive cells, the human foreskin keratinocyte. We incubated keratinocytes in the presence of 1,25-(OH)2D (from 10(-11)-10(-8) M) in medium containing albumin (from 0.1-10%) or serum (from 0.1-10%) for 4 h [to inhibit the 25-hydroxyvitamin D (250HD) 1 alpha-hydroxylase] or 16 h (to induce the 250HD 24-hydroxylase) before evaluating [3H]250HD metabolism by these cells during a 1-h incubation in serum- and albumin-free medium. The free fraction of 1,25-(OH)2D was determined in each medium by centrifugal ultrafiltration and varied from 36% to 0.57% in direct proportion to the albumin or serum in the medium. Increasing the serum or albumin concentration in the medium increased the concentration of total 1,25-(OH)2D needed to inhibit its own production or stimulate that of 24,25-(OH)2D. In contrast, the concentration of free 1,25-(OH)2D needed to half-maximally inhibit its own production or induce 24,25-(OH)2D production remained constant at approximately 10(-11) M. We conclude that the free, not the total, 1,25-(OH)2D concentration regulates 250HD metabolism by keratinocytes, that DBPs do not facilitate 1,25-(OH)2D entry into the cell, and that these cells sense only free 1,25-(OH)2D.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2463902     DOI: 10.1210/endo-124-2-649

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  40 in total

Review 1.  Immunomodulation by vitamin D: implications for TB.

Authors:  Rene F Chun; John S Adams; Martin Hewison
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

2.  Association of 25-hydroxyvitamin D with areal and volumetric measures of bone mineral density and parathyroid hormone: impact of vitamin D-binding protein and its assays.

Authors:  T O Jemielita; M B Leonard; J Baker; S Sayed; B S Zemel; J Shults; R Herskovitz; M R Denburg
Journal:  Osteoporos Int       Date:  2015-09-10       Impact factor: 4.507

3.  Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein.

Authors:  F F Safadi; P Thornton; H Magiera; B W Hollis; M Gentile; J G Haddad; S A Liebhaber; N E Cooke
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

4.  Race, vitamin D-binding protein gene polymorphisms, 25-hydroxyvitamin D, and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Jared P Reis; Erin D Michos; Elizabeth Selvin; James S Pankow; Pamela L Lutsey
Journal:  Am J Clin Nutr       Date:  2015-04-29       Impact factor: 7.045

5.  Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction.

Authors:  Jennifer C Lai; Daniel D Bikle; Blanca Lizaola; Hilary Hayssen; Norah A Terrault; Janice B Schwartz
Journal:  Liver Int       Date:  2015-03-27       Impact factor: 5.828

6.  The unsettled science of nonrenal calcitriol production and its clinical relevance.

Authors:  J Wesley Pike; Mark B Meyer
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

7.  Biomarkers of Vitamin D Status and Risk of ESRD.

Authors:  Casey M Rebholz; Morgan E Grams; Pamela L Lutsey; Andrew N Hoofnagle; Jeffrey R Misialek; Lesley A Inker; Andrew S Levey; Elizabeth Selvin; Chi-Yuan Hsu; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2015-10-23       Impact factor: 8.860

8.  Vitamin D-binding protein, circulating vitamin D and risk of renal cell carcinoma.

Authors:  Alison M Mondul; Stephanie J Weinstein; Kristin A Moy; Satu Männistö; Demetrius Albanes
Journal:  Int J Cancer       Date:  2014-01-30       Impact factor: 7.396

9.  A possible role of vitamin D receptors in regulating vitamin D activation in the kidney.

Authors:  K Iida; T Shinki; A Yamaguchi; H F DeLuca; K Kurokawa; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

Review 10.  The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control.

Authors:  F C Campbell; Haibo Xu; M El-Tanani; P Crowe; V Bingham
Journal:  Biochem Pharmacol       Date:  2009-09-06       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.